Kapil Dhingra

Dr. Dhingra founded KAPital Consulting, LLC, in 2008, a company dedicated to helping biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial advances in oncology. From 1999 to 2008, Dr. Dhingra served in positions of increasing responsibility at Hoffmann‐La Roche, including Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. From 1989 to 1996, he was a faculty member at The University of Texas M.D. Anderson Cancer Center where he led a successful laboratory as well as clinical research program.

Throughout his industry career, Dr. Dhingra maintained an active faculty appointment, at Indiana University School of Medicine from 1997 to 1999, and at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008. Dr. Dhingra holds an MBBS. (equivalent to US M.D.) degree from the All India Institute of Medical Sciences (AIIMS), and has performed postgraduate work at the AIIMS, the Lincoln Medical and Mental Health Center (New York Medical College), Bronx NY and Emory University School of Medicine, Atlanta GA. He is Board‐certified in Internal Medicine and Medical Oncology. Dr. Dhingra is currently Chairman of Board of LAVA Therapeutics and a member of Boards of Autolus (NASDAQ AUTL), Replimune, Inc (NASDAQ REPL), Black Diamond Therapeutics (NASDAQ BDTX) and, Median Technologies (France). In addition, he is an advisor to several biotechnology and pharmaceutical companies and healthcare organizations. He is also a member of the NCI Experimental Therapeutics panel. He has previously served on the Boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, Epitherapeutics, Advanced Accelerator Applications, Exosome Diagnostics, and, Five Prime, which were acquired by major pharmaceutical companies.